Simms Michael J 4/A
4/A · Alexza Pharmaceuticals Inc. · Filed Dec 21, 2009
Insider Transaction Report
Form 4/AAmended
Simms Michael J
SVP, Operations & Manufact
Transactions
- Sale
Common Stock
2009-12-16$2.41/sh−3,092$7,443→ 32,988 total - Sale
Common Stock
2009-12-18$2.13/sh−4,962$10,554→ 26,312 total - Sale
Common Stock
2009-12-17$2.20/sh−1,713$3,770→ 31,274 total
Footnotes (5)
- [F1]Represents shares issued as restricted stock units (the "RSU") under the Issuer's 2005 Equity Incentive Plan pursuant to the terms of the Issuer's 2009-2010 Performance Based Incentive Program. The RSU vested, and shares were delivered to the Reporting Person, upon the Issuer's submission of a New Drug Application for the Issuer's AZ-004 (Staccato loxapine) product candidate on December 11, 2009.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 23, 2009.
- [F3]All of the shares sold were within a $1.00 price range between $2.26 to $2.50 per share, with a weighted average price per share of $2.4071. Upon request, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F4]All of the shares sold were within a $1.00 price range between $2.15 to $2.3299 per share, with a weighted average price per share of $2.2007. Upon request, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F5]All of the shares sold were within a $1.00 price range between $2.05 to $2.21 per share, with a weighted average price per share of $2.1269. Upon request, the Reporting Person will provide full information regarding the number of shares sold at each separate price.